Analyst Jason McCarthy of Maxim Group reiterated a Buy rating on Kairos Pharma, Ltd., retaining the price target of $4.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason McCarthy has given his Buy rating due to a combination of factors related to the promising developments at Kairos Pharma, Ltd. The company is currently conducting a Phase 2 trial for its drug ENV-105 in combination with Erleada, targeting metastatic castration-resistant prostate cancer (mCRPC). The interim safety data reported in July was positive, which has contributed to a significant increase in KAPA’s stock value.
The upcoming interim efficacy data is expected to be a pivotal moment, as it could demonstrate the drug’s ability to re-sensitize tumors to anti-androgen therapy, potentially extending progression-free survival for patients. Additionally, the biotech sector has been performing well, further supporting the stock’s upward trajectory. The anticipated positive outcomes from the ongoing trials and the upcoming Key Opinion Leader event are seen as key catalysts for future growth, reinforcing the Buy recommendation.
McCarthy covers the Healthcare sector, focusing on stocks such as OS Therapies Incorporated, Capricor Therapeutics, and Brainstorm Cell Therapeutics. According to TipRanks, McCarthy has an average return of -17.2% and a 32.26% success rate on recommended stocks.